Revolutionizing Eye Treatment: The Future of Non-Invasive Therapy
May 27, 2024, 3:50 am
The recent presentation at ARVO 2024 by PharmAbcine's U.S. subsidiary, Wincal Biopharm, has sparked excitement in the medical community. Their innovative eye drop formulations have shown promising results in animal studies, potentially changing the landscape of eye disease treatment.
WincalBio's proprietary Ocular Penetration Carrier (OPC) screening platform has opened new possibilities for delivering therapeutic antibodies directly into the eyes. By eliminating the need for invasive intravitreal injections, patients may soon have the option to administer treatment conveniently at home using eye drops.
During the presentation, WincalBio showcased the effectiveness of their OPC platform with anti-VEGF treatments like Eylea and Beovu. In a mouse model, their eye drop formulations demonstrated significant reduction in lesion size and vascular leakage, rivaling the efficacy of traditional injections.
Dr. Venice Chiueh, Project leader at WincalBio, emphasized the importance of developing eye drop formulations to enhance patient convenience and reduce treatment reluctance. The team is dedicated to achieving successful outcomes in upcoming studies and clinical trials.
Dr. TaeWeon Lee, Chief Scientific Officer at WincalBio, highlighted the potential impact of their research on VC investment opportunities and corporate partnerships. The goal is to expand this innovative technology to various eye disease treatments, providing patients with more accessible and convenient care.
The future of eye treatment is evolving, thanks to WincalBio's groundbreaking work. With their focus on patient-centric solutions and cutting-edge technology, the days of needle injections for eye diseases may soon be a thing of the past.
WincalBio's proprietary Ocular Penetration Carrier (OPC) screening platform has opened new possibilities for delivering therapeutic antibodies directly into the eyes. By eliminating the need for invasive intravitreal injections, patients may soon have the option to administer treatment conveniently at home using eye drops.
During the presentation, WincalBio showcased the effectiveness of their OPC platform with anti-VEGF treatments like Eylea and Beovu. In a mouse model, their eye drop formulations demonstrated significant reduction in lesion size and vascular leakage, rivaling the efficacy of traditional injections.
Dr. Venice Chiueh, Project leader at WincalBio, emphasized the importance of developing eye drop formulations to enhance patient convenience and reduce treatment reluctance. The team is dedicated to achieving successful outcomes in upcoming studies and clinical trials.
Dr. TaeWeon Lee, Chief Scientific Officer at WincalBio, highlighted the potential impact of their research on VC investment opportunities and corporate partnerships. The goal is to expand this innovative technology to various eye disease treatments, providing patients with more accessible and convenient care.
The future of eye treatment is evolving, thanks to WincalBio's groundbreaking work. With their focus on patient-centric solutions and cutting-edge technology, the days of needle injections for eye diseases may soon be a thing of the past.